JPH1042868A - Activation method of immobilized papain - Google Patents
Activation method of immobilized papainInfo
- Publication number
- JPH1042868A JPH1042868A JP21601896A JP21601896A JPH1042868A JP H1042868 A JPH1042868 A JP H1042868A JP 21601896 A JP21601896 A JP 21601896A JP 21601896 A JP21601896 A JP 21601896A JP H1042868 A JPH1042868 A JP H1042868A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- papain
- immobilized
- immobilized papain
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019834 papain Nutrition 0.000 title claims abstract description 59
- 239000004365 Protease Substances 0.000 title claims abstract description 58
- 108090000526 Papain Proteins 0.000 title claims abstract description 57
- 229940055729 papain Drugs 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000004913 activation Effects 0.000 title claims description 22
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 24
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 14
- 235000019393 L-cystine Nutrition 0.000 claims abstract description 14
- 239000004158 L-cystine Substances 0.000 claims abstract description 14
- 229960003067 cystine Drugs 0.000 claims abstract description 14
- 235000013878 L-cysteine Nutrition 0.000 claims abstract description 9
- 239000004201 L-cysteine Substances 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 abstract description 25
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 229940088598 enzyme Drugs 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 8
- 239000000243 solution Substances 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229920001661 Chitosan Polymers 0.000 description 15
- 238000000354 decomposition reaction Methods 0.000 description 15
- 229960002433 cysteine Drugs 0.000 description 13
- 230000002797 proteolythic effect Effects 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 235000019830 sodium polyphosphate Nutrition 0.000 description 6
- 230000003100 immobilizing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920000388 Polyphosphate Polymers 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000001205 polyphosphate Substances 0.000 description 4
- 235000011176 polyphosphates Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 4
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000004278 EU approved seasoning Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- -1 polysaccharide ion Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
(57)【要約】
【課題】 固定化パパインを用いて、蛋白質や蛋白質の
部分分解物のようなポリペプチドを回分分解反応する際
に、食品への利用が許可されていない薬品を使用せずに
固定化パパインの酵素活性を賦活化する方法を提供す
る。
【解決手段】 固定化パパインを0.1〜5.0重量%
のメタリン酸と、0.07〜3.45重量%のL−シス
テインまたは0.5〜7.5重量%のL−シスチンを含
む混合水溶液中で処理することによって、未処理のもの
よりも良好な活性及びその活性の持続性が得られる固定
化パパインの賦活化方法に関する。(57) [Summary] [PROBLEMS] When using a fixed papain to batch-degrade a polypeptide such as a protein or a partially degraded product of a protein without using a drug not permitted to be used in foods And a method for activating the enzyme activity of immobilized papain. SOLUTION: 0.1 to 5.0% by weight of immobilized papain is used.
Better than untreated by treating in a mixed aqueous solution containing 0.07 to 3.45% by weight of L-cysteine or 0.5 to 7.5% by weight of L-cystine. The present invention relates to a method for activating immobilized papain capable of obtaining a high activity and a long-lasting activity.
Description
【0001】[0001]
【発明の属する技術分野】本発明は、調味料,乳タンパ
ク質の部分分解物などの機能性食品素材の製造など食品
製造分野で用いられる担体にパパインを固定化した固定
化パパインの工業的利用において、安全性が高く、か
つ、極めて有効に固定化パパインの活性を発現させるこ
とができる賦活化方法に関するものである。The present invention relates to the industrial use of immobilized papain in which papain is immobilized on a carrier used in the field of food production such as production of functional food materials such as seasonings and partially decomposed products of milk protein. The present invention relates to an activation method which is highly safe and can express the activity of immobilized papain extremely effectively.
【0002】[0002]
【従来の技術】パパインは、パパイヤを起源とする植物
由来のタンパク質分解酵素であるが、食品用酵素として
調味料の製造,機能性素材の製造等の目的で幅広く利用
されている。2. Description of the Related Art Papain is a plant-derived proteolytic enzyme derived from papaya and is widely used as a food enzyme for the purpose of producing seasonings, producing functional materials, and the like.
【0003】該分解酵素は、活性中心の一つのシステイ
ンを有するシステインプロテアーゼに分類されるが、シ
ステイン中のスルフヒドリル基は、反応性が高く、微量
の金属イオン,酸化剤などにより容易に酸化され、失活
する事が知られている。このため、エチレンジアミン四
酢酸(以下EDTAという)などのキレート剤とスルフ
ヒドリル基を有するシステインを、反応基質中に共存さ
せた状態で基質と反応させる方法は、「メソッド イン
エンチモロジー」19巻226〜244頁(“ Metho
ds in enzymology”,Academic press社発行)に記載さ
れている。The degrading enzymes are classified as cysteine proteases having one cysteine as an active center. The sulfhydryl group in cysteine has high reactivity and is easily oxidized by trace amounts of metal ions, oxidizing agents and the like. It is known to be deactivated. For this reason, a method of reacting a chelating agent such as ethylenediaminetetraacetic acid (hereinafter referred to as EDTA) and a cysteine having a sulfhydryl group with a substrate in a state where the cysteine coexists in the reaction substrate is described in "Method in Entology", Vol. 19, pp. 226-244. (“Metho
ds in enzymology ”, published by Academic press).
【0004】本出願人はキトサンをベースとした酵素固
定化用担体に酵素を固定化させ、これをEDTAとシス
テイン塩酸塩の混合溶液で処理し、賦活化させることを
特願平7−277046号で開示した。又、「ジャーナ
ル オブ ファーメンテイション アンド バイオエン
ジニアリング」(“Jurnal of fermentation and bioen
gineering ”78,3,241-245(1994))には、同様の考えで
ラテックス微粒子に固定化した固定化パパインを用い
て、その基質中にEDTAとシステインを添加し、連続
的な分解反応を行う記載がある。しかし、食品製造を考
えた場合、EDTAは使用が認められていないため問題
がある。[0004] The applicant of the present invention has disclosed a method of immobilizing an enzyme on a chitosan-based carrier for immobilizing an enzyme, treating the enzyme with a mixed solution of EDTA and cysteine hydrochloride, and activating the same (Japanese Patent Application No. Hei 7-277046). Disclosed. Also, “Journal of fermentation and bioengineering”
gineering "78,3,241-245 (1994)) describes the use of immobilized papain immobilized on latex microparticles based on the same idea and adding EDTA and cysteine to the substrate to perform a continuous decomposition reaction. However, there is a problem in food production because EDTA is not approved for use.
【0005】[0005]
【発明が解決しようとする課題】食品製造に供する固定
化パパインを用いて、蛋白質や蛋白質の部分分解物のよ
うなポリペプチドを回分分解反応する際に、食品への利
用が許可されていないEDTAを使用しないで固定化パ
パインの酵素活性を賦活化する方法を提供するものであ
る。SUMMARY OF THE INVENTION When immobilized papain used for food production is subjected to batch decomposition reaction of polypeptides such as proteins and partially decomposed products of proteins, EDTA which is not permitted to be used for food is not permitted. The present invention provides a method for activating the enzyme activity of immobilized papain without using the same.
【0006】[0006]
【課題を解決するための手段】本発明は、固定化パパイ
ンを0.1〜5.0重量%のメタリン酸と、0.07〜
3.45重量%のL−システインまたは0.5〜7.5
重量%のL−シスチンを含む混合水溶液中で処理するこ
とによって、未処理のものよりも良好な活性とその活性
の持続性が得られる固定化パパインの賦活化方法に関す
るものである。SUMMARY OF THE INVENTION According to the present invention, immobilized papain is prepared by adding 0.1 to 5.0% by weight of metaphosphoric acid to 0.07 to 5.0% by weight.
3.45% by weight of L-cysteine or 0.5 to 7.5
The present invention relates to a method for activating immobilized papain, in which a treatment in a mixed aqueous solution containing L-cystine in an amount of more than 1% by weight gives a better activity and a longer-lasting activity than that of an untreated product.
【0007】[0007]
【発明の実施の形態】本発明の固定化パパインとは、担
体に既述のタンパク質分解酵素であるパパインを固定化
したものであり、固定化パパインにおいて、パパインを
固定化させる担体としては、合成高分子イオン交換体、
多糖類系イオン交換体及びシリカゲル,ガラス等の無機
系の担体等が挙げられるが、特に限定されるものではな
い。出願人が特公平1−16420号公報,特公昭63
−54285号公報に開示した方法で得られる粒状多孔
質キトサン及び架橋化粒状多孔質キトサン、及び特願平
7−277046号で開示した粒状多孔質キトサンをカ
ラギーナンの水溶液に分散し、次いで多官能性試薬を反
応せしめて得た酵素固定化用担体等のキトサンを担体と
してパパインを固定化した固定化パパインの場合、特に
優れた効果を発揮する。BEST MODE FOR CARRYING OUT THE INVENTION The immobilized papain of the present invention is obtained by immobilizing papain, which is the above-mentioned protease, on a carrier. In the immobilized papain, the carrier for immobilizing papain is synthetic. Polymer ion exchanger,
Examples thereof include polysaccharide ion exchangers and inorganic carriers such as silica gel and glass, but are not particularly limited. Applicant filed Japanese Patent Publication No. 1-16420, Japanese Examined Patent Publication No. 63
The particulate porous chitosan and the crosslinked particulate porous chitosan obtained by the method disclosed in JP-A-54285 and the particulate porous chitosan disclosed in Japanese Patent Application No. 7-277046 are dispersed in an aqueous solution of carrageenan, and then polyfunctional. In the case of immobilized papain obtained by immobilizing papain using chitosan such as an enzyme immobilization carrier obtained by reacting a reagent as a carrier, a particularly excellent effect is exhibited.
【0008】本発明で用いられるメタリン酸とは、平均
重合度3の直鎖ポリリン酸,ヘキサメタリン酸であり、
平均重合度3の直鎖ポリリン酸,ヘキサメタリン酸は溶
解性の面からそのナトリウム塩を用いることが好まし
い。また、本発明で用いられるL−システインは、溶解
性の面からその塩酸塩を用いることが特に好ましい。賦
活化処理は、固定化パパインをメタリン酸とL−システ
インまたはL−シスチンを含む混合水溶液中に加え撹拌
することによって行われ、メタリン酸、もしくは、L−
システイン,L−シスチンのいずれかの単独処理ではそ
の効果がない。The metaphosphoric acid used in the present invention is a linear polyphosphoric acid having an average degree of polymerization of 3 and hexametaphosphoric acid.
It is preferable to use sodium salt of linear polyphosphoric acid and hexametaphosphoric acid having an average degree of polymerization of 3 from the viewpoint of solubility. It is particularly preferable to use the hydrochloride of L-cysteine used in the present invention from the viewpoint of solubility. The activation treatment is carried out by adding immobilized papain to a mixed aqueous solution containing metaphosphoric acid and L-cysteine or L-cystine, and stirring the mixture.
A single treatment with either cysteine or L-cystine has no effect.
【0009】処理液中のメタリン酸の濃度は、賦活化の
効果の点から0.1重量%、より好ましくは0.5重量
%以上であるが、高濃度では溶解性低下や粘度の増加が
起こる事から5.0重量%、より好ましくは2.0重量
%以下で用いられる。混合使用されるL−システインの
濃度は賦活化の効果の点から0.07重量%、より好ま
しくは、0.14重量%以上が好ましいが、高濃度では
溶解性が低下する事から3.45重量%、より好ましく
は1.38重量%以下が好ましい。The concentration of metaphosphoric acid in the treatment solution is 0.1% by weight, more preferably 0.5% by weight or more from the viewpoint of the effect of activation, but at a high concentration, the solubility decreases and the viscosity increases. From the viewpoint of occurrence, it is used at 5.0% by weight, more preferably at 2.0% by weight or less. The concentration of L-cysteine used as a mixture is preferably 0.07% by weight, more preferably 0.14% by weight or more from the viewpoint of the effect of activation. However, at a high concentration, the solubility is reduced to 3.45%. % By weight, more preferably 1.38% by weight or less.
【0010】また、処理液中のL−シスチンの濃度は、
賦活化の効果の点から0.5重量%、より好ましくは
1.5重量%以上が好ましいが、高濃度では溶解性が低
下する事から7.5重量%、より好ましくは、5.0重
量%以下が好ましい。[0010] The concentration of L-cystine in the treatment solution is as follows:
It is preferably 0.5% by weight, more preferably 1.5% by weight or more from the viewpoint of the effect of activation, but at a high concentration, 7.5% by weight, more preferably 5.0% by weight because solubility is reduced. % Or less is preferable.
【0011】賦活化の処理時間、担体と該混合水溶液の
容積比は、操作性との関連から2〜12時間、1:2〜
1:10が好ましく、処理温度は、活性を低下させない
点から室温以下が好ましい。賦活化処理終了後、純水で
充分洗浄し、活性の高い固定化パパインを得る。賦活化
処理は、パパインを固定化した固定化パパインの使用前
に行っても、回分分解反応で使用後、固定化パパインを
再使用するときに、この固定化パパインを賦活化処理す
ることも可能である。The activation treatment time and the volume ratio between the carrier and the mixed aqueous solution are 2 to 12 hours, 1: 2 to 2 in view of the operability.
1:10 is preferable, and the treatment temperature is preferably room temperature or lower from the viewpoint of not lowering the activity. After the activation treatment, the resultant is sufficiently washed with pure water to obtain highly active immobilized papain. Even if the activation treatment is performed before using immobilized papain with immobilized papain, this immobilized papain can be activated when reused after use in batch decomposition reaction It is.
【0012】[0012]
【実施例】以下に、本発明を実施例をあげて説明する
が、本発明は、この範囲に限定されるものではない。な
お、固定化パパインのタンパク質分解活性測定法は、次
の方法により測定した。EXAMPLES The present invention will be described below with reference to examples, but the present invention is not limited to these ranges. The proteolytic activity of the immobilized papain was measured by the following method.
【0013】《固定化パパインの活性測定方法》 (1)100gのカゼインを、0.05M−トリス塩酸
緩衝液(pH8.0)1,000mlに、湯浴中で加温し
て溶解させ、基質溶液とする。 (2)固定化用担体にパパインを固定した固定化パパイ
ン1mlに、基質溶液50mlを添加し、37℃10分間撹
拌する。 (3)反応終了後、上清を1ml採取し、5%トリクロロ
酢酸水溶液3mlを添加する。 (4)3,500rpm で遠心分離を15分行い、上清の
280nmにおける吸光度(c)を分光光度計(ベックマ
ン(株)製、型式:DU−640)で光路長1cmの石英
セルで測定する。測定に際しては、測定値が0.5を超
えない様に希釈する(希釈倍率)。 (5)ブランクとして、固定化パパインの代りに未酵素
固定の固定化用担体を用いて上述と同様の操作により2
80nmにおける吸光度(d)を測定する。このときの希
釈率は(4)と同様とする。 (6)固定化パパインの活性は、次式により算出する。 固定化パパインの活性(U/(ml・担体))=0.4×
(c−d)×希釈倍率<< Method of Measuring Activity of Immobilized Papain >> (1) 100 g of casein was dissolved in 1,000 ml of 0.05 M Tris-HCl buffer (pH 8.0) by heating in a hot water bath. Make a solution. (2) 50 ml of a substrate solution is added to 1 ml of immobilized papain having papain immobilized on a carrier for immobilization, followed by stirring at 37 ° C. for 10 minutes. (3) After completion of the reaction, 1 ml of the supernatant is collected, and 3 ml of a 5% aqueous solution of trichloroacetic acid is added. (4) Centrifugation is performed at 3,500 rpm for 15 minutes, and the absorbance (c) at 280 nm of the supernatant is measured with a spectrophotometer (manufactured by Beckman KK, model: DU-640) in a quartz cell having a 1 cm optical path length. . At the time of measurement, dilution is performed so that the measured value does not exceed 0.5 (dilution ratio). (5) As a blank, a non-enzyme-fixed immobilization carrier was used in place of immobilized papain, and the same operation was performed as described above.
The absorbance (d) at 80 nm is measured. The dilution ratio at this time is the same as that in (4). (6) The activity of immobilized papain is calculated by the following equation. Activity of immobilized papain (U / (ml · carrier)) = 0.4 ×
(Cd) x dilution ratio
【0014】〔実施例1〕脱アセチル化度79%、平均
分子量が58,000のキトサン210gを3.5%酢
酸水溶液2,790gに溶解した。該キトサン酸性水溶
液を、7%水酸化ナトリウム,20%エタノール,73
%水よりなる凝固液中に滴下し、キトサンを粒状多孔質
に凝固再生後、中性になるまで充分水洗し、平均粒径1
mmの再生粒状多孔質キトサン2,995ml(湿潤)を得
た。Example 1 210 g of chitosan having a degree of deacetylation of 79% and an average molecular weight of 58,000 was dissolved in 2,790 g of a 3.5% acetic acid aqueous solution. The chitosan acidic aqueous solution was mixed with 7% sodium hydroxide, 20% ethanol, 73%
% Chitosan after solidifying and regenerating chitosan into a granular porous material, and thoroughly washing with water until neutral, and an average particle size of 1%.
2,995 ml (wet) of regenerated granular porous chitosan having a thickness of 2 mm were obtained.
【0015】次に再生粒状多孔質キトサン500mlを、
2重量%カッパカラギーナン水溶液(ハーキュリーズ・
ジャパン(株)製、商品名GENUVISCO Type CSW-2)1,
000mlに加え、24時間撹拌した後、カッパカラギー
ナン水溶液を濾過して除き、5.6重量%エピクロロヒ
ドリン500mlと5N−KOH 120mlをそれぞれ加
え70℃で2時間撹拌し反応させた。反応終了後、充分
水洗し、酵素固定化用担体を得た。Next, 500 ml of the regenerated granular porous chitosan is
2% by weight kappa carrageenan aqueous solution (Hercules ・
Japan Co., Ltd., product name GENUVISCO Type CSW-2) 1,
After stirring for 24 hours, the aqueous solution of kappa carrageenan was removed by filtration, and 500 ml of 5.6% by weight epichlorohydrin and 120 ml of 5N-KOH were added, and the mixture was stirred and reacted at 70 ° C. for 2 hours. After completion of the reaction, the resultant was sufficiently washed with water to obtain a carrier for enzyme immobilization.
【0016】得られた酵素固定化用担体100mlを1%
パパイン水溶液500mlに添加し室温で2時間撹拌し
た。撹拌終了後、充分水洗し、100mlの固定化パパイ
ンを得た。[0016] 100 ml of the obtained enzyme-immobilizing carrier was added to 1%
It was added to 500 ml of papain aqueous solution and stirred at room temperature for 2 hours. After completion of the stirring, the mixture was sufficiently washed with water to obtain 100 ml of immobilized papain.
【0017】次いで、固定化パパインの各1mlに賦活化
剤である直鎖ポリリン酸ナトリウム(和光純薬工業
(株)製)を1.0重量%とし、これにL−システイン
塩酸塩(和光純薬工業(株)製)5mlまたはL−シスチ
ン(和光純薬工業(株)製)5mlを表1に示す如く濃度
を変更し混合して、10℃で10時間撹拌して賦活化処
理を行った後、充分水洗した。水洗後、固定化パパイン
のタンパク質分解活性を測定した結果を表1に示した。Next, 1% of the immobilized papain was added with 1.0% by weight of linear sodium polyphosphate (manufactured by Wako Pure Chemical Industries, Ltd.) as an activator, and L-cysteine hydrochloride (Wako Pure Chemical Industries, Ltd.) was added thereto. 5 ml of Yakuhin Kogyo Co., Ltd. or 5 ml of L-cystine (Wako Junyaku Kogyo Co., Ltd.) was mixed at different concentrations as shown in Table 1, and stirred at 10 ° C. for 10 hours to perform an activation treatment. After that, it was sufficiently washed with water. After washing with water, the results of measuring the proteolytic activity of the immobilized papain are shown in Table 1.
【0018】[0018]
【表1】 [Table 1]
【0019】表1より、賦活化剤中の直鎖ポリリン酸ナ
トリウムの濃度を1.0重量%としたとき混合するL−
システイン塩酸塩濃度が0.2〜2.0重量%、即ち、
L−システイン換算濃度が0.14〜1.38重量%、
または直鎖ポリリン酸ナトリウムと混合するL−シスチ
ン濃度が1.5〜5.0重量%のときに高い活性が得ら
れ、賦活化未処理の固定化パパインに対して高い活性値
を有することが明らかである。As shown in Table 1, when the concentration of the linear sodium polyphosphate in the activator is 1.0% by weight, the L-
Cysteine hydrochloride concentration of 0.2-2.0% by weight, ie
L-cysteine conversion concentration is 0.14 to 1.38% by weight,
Alternatively, high activity is obtained when the concentration of L-cystine mixed with linear sodium polyphosphate is 1.5 to 5.0% by weight, and high activity value with respect to immobilized papain which has not been activated. it is obvious.
【0020】〔実施例2〕実施例1と同様にして得られ
た固定化パパインの各1mlを、L−システイン塩酸塩を
0.5重量%としてこれに直鎖ポリリン酸ナトリウム5
mlまたはヘキサメタリン酸ナトリウム(和光純薬工業
(株)製)5mlを表2に示す如く濃度を変更し混合し
て、10℃で10時間撹拌して賦活化処理を行った後、
充分水洗した。水洗後、固定化パパインのタンパク質分
解活性を測定した結果を表2に示した。Example 2 1 ml of immobilized papain obtained in the same manner as in Example 1 was added to 0.5% by weight of L-cysteine hydrochloride.
After changing the concentration as shown in Table 2 and mixing with 5 ml of sodium hexametaphosphate (manufactured by Wako Pure Chemical Industries, Ltd.), stirring at 10 ° C. for 10 hours, and performing an activation treatment,
Washed thoroughly with water. After washing with water, the results of measuring the proteolytic activity of the immobilized papain are shown in Table 2.
【0021】[0021]
【表2】 [Table 2]
【0022】表2より、賦活化剤中のL−システイン塩
酸塩濃度を0.5重量%、即ちL−システイン換算濃度
が0.35重量%としたときこれに混合する直鎖ポリリ
ン酸ナトリウムまたはヘキサメタリン酸ナトリウムの濃
度が0.5〜2.0重量%のときに高い活性が得られ、
賦活化未処理の固定化パパインに対して高い活性値を有
することが明らかである。According to Table 2, when the concentration of L-cysteine hydrochloride in the activator is 0.5% by weight, that is, when the concentration in terms of L-cysteine is 0.35% by weight, linear sodium polyphosphate mixed therewith or High activity is obtained when the concentration of sodium hexametaphosphate is 0.5 to 2.0% by weight,
It is evident that it has a high activity value against immobilized untreated papain.
【0023】〔実施例3〕実施例1と同様にして得られ
た固定化パパインの各1mlを、L−シスチンを4.0重
量%としてこれに直鎖ポリリン酸ナトリウム5mlまたは
ヘキサメタリン酸ナトリウム5mlを表3に示す如く濃度
を変更し混合して、10℃で10時間撹拌して賦活化処
理を行った後、充分水洗した。水洗後、固定化パパイン
のタンパク質分解活性を測定した結果を表3に示した。Example 3 1 ml of immobilized papain obtained in the same manner as in Example 1 was added to 4.0% by weight of L-cystine, and 5 ml of sodium linear polyphosphate or 5 ml of sodium hexametaphosphate was added thereto. After changing the concentration as shown in Table 3, mixing and stirring at 10 ° C. for 10 hours to perform an activation treatment, the mixture was sufficiently washed with water. After washing with water, the results of measuring the proteolytic activity of the immobilized papain are shown in Table 3.
【0024】[0024]
【表3】 [Table 3]
【0025】表3より、賦活化剤中のL−シスチン濃度
を4.0重量%としたときこれに混合する直鎖ポリリン
酸ナトリウムまたはヘキサメタリン酸ナトリウムの濃度
が0.5〜2.0重量%のときに高い活性が得られ、賦
活化未処理に対して高い活性値を有することが明らかで
ある。According to Table 3, when the concentration of L-cystine in the activator is 4.0% by weight, the concentration of sodium linear polyphosphate or sodium hexametaphosphate mixed with this is 0.5 to 2.0% by weight. It is clear that a high activity is obtained at the time of and that the compound has a high activity value with respect to the untreated activation.
【0026】〔実施例4〕実施例1と同様にして得られ
た固定化パパイン1mlを採取し、カゼインの回分分解反
応の前に、1.0重量%直鎖ポリリン酸ナトリウムと
0.5重量%L−システイン塩酸塩を含む混合水溶液5
mlに入れ、5℃、10時間賦活化処理し水洗後、分解反
応を行う。これを5回繰り返し賦活化処理と回分分解反
応を行った(A)。同様に固定化パパイン1mlを採取
し、カゼインの回分分解反応の前に、1.0重量%直鎖
ポリリン酸ナトリウムと4.0重量%L−シスチンを含
む混合水溶液5mlに入れ5℃、10時間賦活化処理し水
洗後、分解反応を行い、これを5回繰り返し回分分解反
応を行った(B)。又、回分分解反応前に賦活化処理を
行わずに5回繰り返し回分分解反応を行った(C)。
(A),(B),(C)の繰り返し回分分解反応後の各
回に於けるタンパク質分解活性を測定した結果を表4に
示した。Example 4 1 ml of immobilized papain obtained in the same manner as in Example 1 was collected, and 1.0% by weight of linear sodium polyphosphate and 0.5% by weight were added before the batch decomposition reaction of casein. % L-cysteine hydrochloride mixed aqueous solution 5
The mixture is put into a ml, activated at 5 ° C. for 10 hours, washed with water, and then subjected to a decomposition reaction. This was repeated five times to perform an activation treatment and a batch decomposition reaction (A). Similarly, 1 ml of immobilized papain was collected and placed in 5 ml of a mixed aqueous solution containing 1.0% by weight of sodium linear polyphosphate and 4.0% by weight of L-cystine at 5 ° C. for 10 hours before the batch decomposition reaction of casein. After activation treatment and washing with water, a decomposition reaction was performed, and this was repeated five times to perform a batch decomposition reaction (B). The batch decomposition reaction was repeated 5 times without performing the activation treatment before the batch decomposition reaction (C).
Table 4 shows the results obtained by measuring the proteolytic activity in each of the repeated batch decomposition reactions (A), (B), and (C).
【0027】[0027]
【表4】 [Table 4]
【0028】表4より、反応前に賦活化処理する事によ
り、繰り返し回分分解反応で高いタンパク質分解活性が
持続していることが明らかである。From Table 4, it is apparent that the activation treatment before the reaction maintains a high proteolytic activity in the repeated batch decomposition reaction.
【0029】〔実施例5〕実施例1と同様にして得られ
た再生粒状多孔質キトサン600mlが含む水を、ジメチ
ルホルムアミドで充分に除去した。該再生粒状多孔質キ
トサン500mlに、ジメチルホルムアミド500mlと1
5.2gのヘキサメチレンジソシアナートを加え、室温
で2時間反応させた。反応残液を除去した後、ジメチル
ホルムアミドで洗浄し、次いで純水で充分洗浄し、イソ
シアナート架橋再生粒状多孔質キトサン担体を得た。Example 5 Water contained in 600 ml of regenerated granular porous chitosan obtained in the same manner as in Example 1 was sufficiently removed with dimethylformamide. 500 ml of dimethylformamide and 500 ml of the regenerated granular porous chitosan
5.2 g of hexamethylene dissocyanate was added and reacted at room temperature for 2 hours. After removing the reaction residual liquid, the resultant was washed with dimethylformamide and then thoroughly washed with pure water to obtain an isocyanate crosslinked regenerated granular porous chitosan carrier.
【0030】担体として、該イソシアナート架橋再生粒
状多孔質キトサン、市販の担体X(日本錬水(株)製の
商品名ダイヤイオンHP−50)、担体Y(日本錬水
(株)製の商品名ダイヤイオンWA−30)、担体Z
(オルガノ(株)製の商品名アンバーライトIRA−9
3)の各15mlを2.5%グルタルアルデヒド水溶液3
0mlに加え、室温で2時間反応させた。反応終了後、水
洗し、1%パパイン水溶液5mlに添加し室温で2時間撹
拌した。撹拌終了後、充分水洗し、夫々15mlの固定化
パパインを得た。As the carrier, the isocyanate cross-linked regenerated granular porous chitosan, a commercially available carrier X (Diaion HP-50, trade name, manufactured by Nippon Rensui Co., Ltd.), and a carrier Y (trade name, manufactured by Nippon Rensui Co., Ltd.) Name Diaion WA-30), carrier Z
(Amberlite IRA-9 manufactured by Organo Corporation)
3) 15 ml each of 2.5% glutaraldehyde aqueous solution 3
0 ml, and reacted at room temperature for 2 hours. After completion of the reaction, the mixture was washed with water, added to 5 ml of a 1% aqueous papain solution, and stirred at room temperature for 2 hours. After completion of the stirring, the mixture was sufficiently washed with water to obtain 15 ml of immobilized papain.
【0031】次いで、各固定化パパイン各1mlを採取
し、1.0重量%直鎖ポリリン酸ナトリウムと0.5重
量%L−システイン塩酸塩を含む混合水溶液5mlに入れ
5℃、10時間賦活化処理し、水洗した。又、同様に各
固定化パパイン1mlを採取し、賦活化剤で処理を行わな
かった。これらの各固定化パパインのタンパク質分解活
性を測定し、その結果を表5に示した。Next, 1 ml of each immobilized papain was collected and placed in 5 ml of a mixed aqueous solution containing 1.0% by weight of sodium linear polyphosphate and 0.5% by weight of L-cysteine hydrochloride, and activated at 5 ° C. for 10 hours. Treated and washed with water. Similarly, 1 ml of each immobilized papain was collected and not treated with the activator. The proteolytic activity of each of these immobilized papains was measured, and the results are shown in Table 5.
【0032】[0032]
【表5】 [Table 5]
【0033】表5より、パパインを固定化する担体が異
っても、固定化パパインを本発明方法で賦活化処理する
事により、未賦活化処理のものより高いタンパク質分解
活性を示すことが明らかである。From Table 5, it can be seen that activation of the immobilized papain by the method of the present invention shows a higher proteolytic activity than that of the unactivated papain even if the carrier on which papain is immobilized is different. It is.
【0034】〔実施例6〕実施例5と同様にして得られ
た各固定化パパインを各1ml採取し、1.0%直鎖ポリ
リン酸ナトリウムと4.0重量%L−シスチンを含む混
合水溶液5mlに入れ、5℃、10時間賦活化処理し、水
洗した。又、同様に各固定化パパイン1mlを採取し、賦
活化剤で処理を行わなかった。これらの各固定化パパイ
ンのタンパク質分解活性を測定し、その結果を表6に示
した。Example 6 1 ml of each immobilized papain obtained in the same manner as in Example 5 was collected, and a mixed aqueous solution containing 1.0% linear sodium polyphosphate and 4.0% by weight L-cystine was obtained. The mixture was placed in 5 ml, activated at 5 ° C. for 10 hours, and washed with water. Similarly, 1 ml of each immobilized papain was collected and not treated with the activator. The proteolytic activity of each of these immobilized papains was measured, and the results are shown in Table 6.
【0035】[0035]
【表6】 [Table 6]
【0036】表6より、パパインを固定化する担体が異
なっても固定化パパインを本発明方法で賦活化処理する
事により、未賦活化処理のものより高いタンパク質分解
活性を示すことが明らかである。From Table 6, it is apparent that the activation treatment of the immobilized papain by the method of the present invention shows a higher proteolytic activity than that of the unactivated treatment even if the carrier on which papain is immobilized is different. .
【発明の効果】本発明の方法は、固定化パパインを用い
てポリペプチドの回分分解反応を行う際に、分解反応の
前に、0.1〜5.0重量%のメタリン酸と、0.07
〜3.45重量%のL−システインまたは0.5〜7.
5重量%のL−シスチンを含む混合水溶液中で、賦活化
処理することにより、活性値が著しく高くなり、効果的
に反応を行うことが出来、また、使用後においても賦活
化することにより、活性値を再び高くすることができる
効果を得ることが出来る。さらに、メタリン酸,L−シ
ステイン,L−シスチンは、食品への使用が許可されて
いる物質であるため、本発明の方法は食品の製造に使用
する事が出来、工業的に有利である。According to the method of the present invention, when performing a batch decomposition reaction of a polypeptide using immobilized papain, 0.1-5.0% by weight of metaphosphoric acid and 0.1% by weight of metaphosphoric acid are added before the decomposition reaction. 07
-3.45% by weight of L-cysteine or 0.5-7.
By performing the activation treatment in a mixed aqueous solution containing 5% by weight of L-cystine, the activity value is remarkably increased, the reaction can be effectively performed, and the activation is performed even after use. The effect that the activity value can be increased again can be obtained. Furthermore, metaphosphoric acid, L-cysteine, and L-cystine are substances that are permitted to be used in foods, so that the method of the present invention can be used for the production of foods, which is industrially advantageous.
フロントページの続き (72)発明者 田村 吉隆 神奈川県座間市東原5−1−83 森永乳業 株式会社栄養科学研究所内 (72)発明者 宮川 博 神奈川県座間市東原5−1−83 森永乳業 株式会社栄養科学研究所内 (72)発明者 越智 浩 神奈川県座間市東原5−1−83 森永乳業 株式会社栄養科学研究所内Continued on the front page (72) Inventor Yoshitaka Tamura 5-1-83 Higashihara, Zama City, Kanagawa Prefecture Morinaga Dairy Co., Ltd. (72) Inventor Hiroshi Miyagawa 5-1-83 Higashihara, Zama City, Kanagawa Prefecture Morinaga Milk Products Co., Ltd. Nutrition Science Laboratory (72) Inventor Hiroshi Ochi 5-1-83 Higashihara, Zama City, Kanagawa Prefecture Morinaga Milk Industry Nutrition Science Laboratory Co., Ltd.
Claims (1)
のメタリン酸と、0.07〜3.45重量%のL−シス
テインまたは0.5〜7.5重量%のL−シスチンを含
む混合水溶液中で処理することを特徴とする固定化パパ
インの賦活化方法。1. An immobilized papain containing 0.1 to 5.0% by weight.
Activation of immobilized papain, characterized in that the treatment is carried out in a mixed aqueous solution containing 0.07 to 3.45% by weight of L-cysteine or 0.5 to 7.5% by weight of L-cystine. Method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21601896A JPH1042868A (en) | 1996-07-29 | 1996-07-29 | Activation method of immobilized papain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21601896A JPH1042868A (en) | 1996-07-29 | 1996-07-29 | Activation method of immobilized papain |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH1042868A true JPH1042868A (en) | 1998-02-17 |
Family
ID=16682019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP21601896A Pending JPH1042868A (en) | 1996-07-29 | 1996-07-29 | Activation method of immobilized papain |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH1042868A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100451110C (en) * | 2005-12-06 | 2009-01-14 | 青岛科技大学 | Novel silicagel supported porous chitosan carrier for enzyme immobilization |
-
1996
- 1996-07-29 JP JP21601896A patent/JPH1042868A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100451110C (en) * | 2005-12-06 | 2009-01-14 | 青岛科技大学 | Novel silicagel supported porous chitosan carrier for enzyme immobilization |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4418147A (en) | Enzyme immobilization in a starch gel | |
JPH0236228B2 (en) | ||
JP3027548B2 (en) | Methods for removing proteins from liquids | |
Kurita et al. | Mercapto-chitins: a new type of supports for effective immobilization of acid phosphatase | |
JPH1042868A (en) | Activation method of immobilized papain | |
CN116410958B (en) | Preparation method of lysozyme inclusion particles and lysozyme inclusion particles | |
JP2560363B2 (en) | Method for purifying chitin or chitosan | |
Hatayama et al. | Immobilization of urease on composite fibre by using a gel formation of cellulose acetate and titanium iso-propoxide | |
JP3062893B2 (en) | Enzymatic degradation of chitin-containing materials | |
JPS61257906A (en) | Packing cosmetic | |
JP2824902B2 (en) | Method for producing enzyme-immobilizing carrier | |
Salazar‐Leyva et al. | Catalytic and operational stability of acidic proteases from monterey sardine (Sardinops sagax caerulea) immobilized on a partially deacetylated chitin support | |
JP3055965B2 (en) | Enzymatic degradation method of chitin-containing material | |
RU2832335C1 (en) | Magnetically separated catalyst for oxidation of organic compounds and method for production thereof | |
RU2770208C1 (en) | Method for obtaining a heterogeneous preparation based on bromelain, immobilized using ion-exchange resins | |
CA2442524A1 (en) | Matrix stabilized enzyme crystals and methods of use | |
RU2788455C1 (en) | Method for obtaining a composite preparation of papain and sodium alginate in the form of a thick solution | |
JP2004065153A (en) | Method for producing immobilized enzyme | |
JPH0679541B2 (en) | Method for producing hydrolyzed gluten | |
Miguezb et al. | Preparation and scanning electronic microscopy study of chitosan/polyvinyl (alcohol)-encapsulated crude urease extract | |
Banchón | Chitosan flakes for papain immobilization: improving the stability and reusability of the enzyme | |
JPH0655151B2 (en) | Method for producing low molecular weight chitosan | |
JPH0517835B2 (en) | ||
JP2002233362A (en) | Method for stabilizing laccase activity and stabilized laccase composition | |
JPS59220187A (en) | Immobilization of enzyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050314 |
|
A521 | Written amendment |
Effective date: 20050426 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
A02 | Decision of refusal |
Effective date: 20050530 Free format text: JAPANESE INTERMEDIATE CODE: A02 |